ArticleBMC medical genomics2026
Genetic polymorphisms and expression of SARS-CoV-2 host entry genes associate with COVID-19 severity in an unvaccinated Moroccan cohort.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHost molecular and genetic factors regulating SARS-CoV-2 entry are increasingly recognized as key determinants of infection susceptibility and disease severity. However, the combined impact of transcriptional and genetic variation in these pathways remains incompletely defined. This study aimed to identify clinically relevant biomarkers associated with COVID-19 outcomes by integrating gene expression and genetic variability analyses of major viral entry factors.
methodsWe analyzed the expression and genetic variability of key SARS-CoV-2 entry-related genes (ACE2, TMPRSS2, FURIN, and NRP1) in 184 severe patients, 182 benign cases, and 180 healthy controls. Gene expression was quantified by qRT-PCR, and six SNPs (rs2285666, rs2070788, rs1475908, rs4702, rs4932178, rs1412115) were genotyped using TaqMan assays.
resultsTMPRSS2 and FURIN were significantly overexpressed in severe COVID-19 patients (p < 0.05) and positively correlated with platelet count (r = 0.34–0.36, p < 0.05). FURIN expression also correlated with viral load (r = 0.40, p = 0.007). Genetically, the TMPRSS2 rs1475908 GG genotype was associated with higher gene expression (p = 0.009), while the A allele conferred protection against disease severity (OR = 0.53, 95% CI: 0.33–0.84, p = 0.006). Conversely, the rs2070788 GA genotype increased infection susceptibility (OR = 1.69, 95% CI: 1.10–2.60, p = 0.048). FURIN rs4702 was significantly associated with both infection risk and severe disease (OR = 1.53, p = 0.002; OR = 1.60, p = 0.012). After FDR correction, the association of rs4702 with infection susceptibility remained statistically significant. Haplotype analyses further supported these findings, highlighting the role of TMPRSS2 in disease severity and FURIN in susceptibility.
conclusionOur findings identify TMPRSS2 and FURIN as biomarkers that integrate transcriptional and genetic signatures. These variants, particularly FURIN rs4702 and TMPRSS2 rs1475908, may hold potential utility for early risk stratification and personalized management of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.